Bristol-Myers Squibb Company Ce (CELG-RI) Bundle
Who Invests in Bristol-Myers Squibb Company Ce and Why?
Who Invests in Bristol-Myers Squibb Company (BMY) and Why?
Bristol-Myers Squibb Company (BMY) attracts a diverse array of investors, each with unique motivations and strategies.
Key Investor Types
- Retail Investors: Individual investors buying small numbers of shares, often influenced by news, earnings reports, and trends in the pharmaceutical sector.
- Institutional Investors: Organizations such as mutual funds, pension funds, and insurance companies. As of Q3 2023, institutional ownership in BMY stood at approximately 80%.
- Hedge Funds: Sophisticated investors employing various strategies. According to SEC filings, hedge funds held around 15% of BMY shares in mid-2023.
Investment Motivations
Diverse investor types are attracted to Bristol-Myers Squibb for several reasons:
- Growth Prospects: Analysts project a compound annual growth rate (CAGR) of 5.5% for the pharmaceutical industry through 2025, with BMY expected to capitalize on this growth.
- Dividends: BMY offers a current dividend yield of approximately 3.10%, appealing to income-focused investors.
- Market Position: With a robust pipeline of drugs, including cancer therapies like Opdivo and Revlimid, BMY holds a significant position in the oncology market.
Investment Strategies
Investors employ various strategies when investing in Bristol-Myers Squibb:
- Long-Term Holding: Many institutional investors adopt a buy-and-hold strategy, banking on BMY's steady growth and reliable dividends.
- Short-Term Trading: Retail investors may engage in short-term trading, influenced by stock price movements post-earnings announcements.
- Value Investing: Value investors might view BMY's current price-to-earnings (P/E) ratio of about 12.5 as an attractive entry point compared to industry averages.
| Investor Type | Percentage Ownership | Typical Investment Strategy | Average Holding Period |
|---|---|---|---|
| Retail Investors | ~20% | Short-Term Trading | 6-12 months |
| Institutional Investors | ~80% | Long-Term Holding | 3-5 years |
| Hedge Funds | ~15% | Value Investing | 1-3 years |
The blend of retail, institutional, and hedge fund investments creates a dynamic shareholder base for Bristol-Myers Squibb, influencing its market performance and strategic direction.
Institutional Ownership and Major Shareholders of Bristol-Myers Squibb Company Ce
Institutional Ownership and Major Shareholders of Bristol-Myers Squibb Company
Bristol-Myers Squibb Company (NYSE: BMY) has seen significant institutional ownership, reflecting strong interest from major investors. As of October 2023, institutional investors collectively hold approximately 80.5% of the company’s outstanding shares.
Top Institutional Investors
Here is a list of some of the largest institutional investors in Bristol-Myers Squibb along with their respective shareholdings:
| Institution Name | Shares Held | Percentage of Ownership |
|---|---|---|
| The Vanguard Group, Inc. | 327,209,097 | 8.0% |
| BlackRock, Inc. | 318,870,000 | 7.8% |
| State Street Corporation | 235,898,400 | 5.8% |
| Wellington Management Company LLP | 190,900,000 | 4.7% |
| Fidelity Management & Research Company LLC | 164,000,000 | 4.0% |
Changes in Ownership
In recent quarters, there have been noticeable shifts in institutional ownership. The latest filings indicate that institutional investors have collectively increased their stakes by approximately 3.2% over the past year. Specifically, investment by The Vanguard Group increased by 1.5%, while BlackRock saw an increase of 2.1% in its holdings.
Impact of Institutional Investors
Institutional investors play a crucial role in the stock price and corporate strategy of Bristol-Myers Squibb. Their buying activity tends to stabilize stock prices, creating a more robust shareholder base. Following the news of positive clinical trial results for its cancer treatment, the stock experienced a surge of 15% in a single week, largely attributed to increased institutional buying. Moreover, these investors often push for strategic decisions that align with long-term value creation, influencing management policies on research and development investments.
Key Investors and Their Influence on Bristol-Myers Squibb Company Ce
Key Investors and Their Impact on Bristol-Myers Squibb Company (BMY)
Bristol-Myers Squibb Company (BMY) has a diverse set of investors, including institutional funds, mutual funds, hedge funds, and individual stakeholders. This array of investors plays a significant role in influencing stock movements and company governance.
Notable Investors
Some of the key investors in Bristol-Myers Squibb include:
- Vanguard Group, Inc. - One of the largest shareholders with approximately 8.1% ownership as of Q3 2023.
- BlackRock, Inc. - Holds around 7.9% of shares, solidifying its status as a principal institutional investor.
- State Street Corporation - Owns about 4.5% of the company's stock, contributing significantly to its institutional holdings.
- Wellington Management Company - Notable for holding approximately 4.3% of shares.
Investor Influence
These investors impact Bristol-Myers Squibb's decisions and stock performance in various ways:
- Voting Power: Shareholders with significant ownership can influence board elections and strategic initiatives.
- Engagement: Institutional investors often engage with management on operational and strategic matters, potentially steering the company's direction.
- Market Perception: Large institutional investments can affect stock prices; strong buying activity often signals confidence in the company.
Recent Moves
Recent developments among key investors have been noteworthy:
- In December 2023, Vanguard increased its stake by 1.2 million shares, demonstrating confidence in the company's future prospects.
- BlackRock reported a decrease in its holdings by 700,000 shares in early Q4 2023, which raised concerns among investors about potential volatility.
- Wellington Management has been consistently increasing its stake, acquiring an additional 300,000 shares during Q3 2023.
Investor Analysis Table
| Investor | Ownership (%) | Recent Activity | Share Changes (Last Quarter) |
|---|---|---|---|
| Vanguard Group, Inc. | 8.1% | Increased Stake | +1.2 million shares |
| BlackRock, Inc. | 7.9% | Decreased Stake | -700,000 shares |
| State Street Corporation | 4.5% | No Significant Change | No change |
| Wellington Management Company | 4.3% | Increased Stake | +300,000 shares |
As the investor landscape evolves, these key players will continue to shape Bristol-Myers Squibb’s strategies and market performance, making them crucial for stakeholders to watch closely.
Market Impact and Investor Sentiment of Bristol-Myers Squibb Company Ce
Market Impact and Investor Sentiment
As of October 2023, the current sentiment among major shareholders of Bristol-Myers Squibb Company (BMY) is predominantly positive. The stock has seen a rise in demand following the approval of its latest immunotherapy treatments, which has contributed to an optimistic outlook among institutional investors.
Recent market reactions illustrate that BMY's stock price has been quite responsive to significant changes in ownership. Notably, following Vanguard Group's recent increase in its stake to 8.1% in early Q3 2023, the stock price surged by 5.2% over the following weeks. In contrast, when a major hedge fund reduced its position by 3.5%, the stock experienced a temporary decline of 2.7%.
Analyst perspectives indicate a cautiously optimistic view on Bristol-Myers Squibb's future, especially after its latest earnings report. Analysts have forecasted a revenue growth of 7% for the next fiscal year, driven by strong performance in the oncology segment. The average price target set by analysts stands at $75, reflecting a potential upside of 10% from current trading levels.
| Investor Name | Stake Owned (%) | Recent Action | Market Reaction (%) |
|---|---|---|---|
| Vanguard Group | 8.1% | Increased stake | +5.2% |
| BlackRock | 7.7% | Stable | +1.1% |
| Capital Research | 6.0% | New Position | +3.0% |
| Fidelity Investments | 5.5% | Reduced stake | -2.7% |
The overall investor sentiment reflects confidence owing to Bristol-Myers Squibb's strong pipeline and recent advancements in drug approvals. Analyst upgrades following strong quarterly earnings have reinforced this sentiment, paving the way for continued interest from both institutional and retail investors.
Bristol-Myers Squibb Company Ce (CELG-RI) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.